Viewing Study NCT01221103


Ignite Creation Date: 2025-12-24 @ 7:49 PM
Ignite Modification Date: 2025-12-29 @ 5:05 PM
Study NCT ID: NCT01221103
Status: UNKNOWN
Last Update Posted: 2011-09-13
First Post: 2010-10-13
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Dexamethasone, Ofatumumab and Bendamustine (DOT) First-line in Mantle-cell Lymphoma(MCL)
Sponsor: Southern Europe New Drug Organization
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module